Required Fields *
Submit Close
Print

Let Our Family Care for Your Family!

Drug Development Program

Advancing Therapies for Patients

SCRI’s Drug Development Program offers sponsors consistent performance and excellence through:

  • Strict adherence to eligibility criteriaDrug Development Unit Lobby
  • A dedicated pharmacokinetic team
  • Rapid accrual
  • Interactive scientific collaboration

Services and Resources:

  • Extensive clinical trials menu
  • Expansive clinic with patient lounge area
  • Private treatment rooms
  • On-site pharmacy for patient convenience
  • Wireless internet and televisions with wireless head phones

Program Growth

SCRI’s Drug Development Unit has experienced an annual average growth rate of 15-20% in patient enrollment.

We are committed to our partners’ goals, and we tailor our teams and processes to meet them. Senior-level management and clinical staff stay involved throughout our working relationship, ensuring strong science and consistent quality every step of the way. We serve as collaborators and research consultants, and we strive to provide informed scientific insights that contribute to success and discovery. And faster answers.

Patient Accrual:

  • 2003: 158 patients
  • 2004: 186 patients
  • 2005: 233 patients
  • 2006: 295 patients
  • 2007: 357 patients
  • 2008: 463 patients
  • 2009: 515 patients
  • 2010: 632 patients
  • 100 first-in-man trials 

Leadership

Dr. Burris Howard A. "Skip", Burris III, M.D., Chief Medical Officer; Executive Director Drug Development Program, has over 20 years of Phase I clinical trial experience. He received his undergraduate degree from the U.S. Military Academy, West Point in 1981 and medical degree from the University of South Alabama in 1985. He then performed his residency and fellowship in hematology/oncology at Brooke Army Medical Center in San Antonio. He is board certified in medical oncology. 
Dr. Infante Jeffrey R. Infante, M.D., Director, Drug Development Program, received his undergraduate degree in 1994 and medical degree in 1999 from the University of Florida and completed his residency at Parkland Memorial Hospital, University of Texas Southwestern Medical Center. He completed his fellowship in medical oncology at Johns Hopkins University School of Medicine in 2006. He also received a master of health science degree in epidemiology at Johns Hopkins University’s Bloomberg School of Public Health. He is board certified in internal medicine and medical oncology.
Dr. Bendell Johanna C. Bendell, M.D., Director, GI Cancer Research Program; Associate Director, Drug Development Program, received her undergraduate degree in 1994 and medical degree in 1998 from the University of Chicago. She completed her internship and residency at Brigham and Women’s Hospital in Boston, as well as a fellowship in adult oncology at Boston’s Dana-Farber Cancer Institute.  She is board certified in internal medicine and medical oncology.
Hendrik-Tobias Arkenau, M.D., Ph.D.; Director, Drug Development Program, Sarah Cannon Research UK has vast experience in Early Oncology Clinical Drug Development with a special interest in gastrointestinal cancer and melanoma. He received his medical degree in 2000 at the Medical School Hanover, Germany, and completed his internship and specialist training in oncology in 2007. Before joining Sarah Cannon Research UK, he was senior clinical fellow at the Royal Marsden Hospital and team leader for Early Drug Development at the Prince of Wales Clinical School at the University of New South Wales, Sydney, Australia.
Dr. Jones Suzanne Jones, Pharm.D., Scientific Director, Drug Development Program, received her undergraduate degree from the University of North Carolina at Chapel Hill in 1987 and her doctor of pharmacy degree from the University of North Carolina at Chapel Hill in 1989. She then completed her residency and fellowship in hematology/oncology at the Audie L. Murphy Veteran’s Hospital and the University of Texas Health Science Center in San Antonio.

Our Team of Professionals:

We have a fully staffed nursing and clinical research team including principal investigators, clinical and research nurses, project and clinical trial managers, data coordinators, regulatory affairs specialists, pharmacy technicians, pharmacokinetic technicians and administrative office support.

Above all else, we are committed to the improvement of patient outcomes and advancement of medical science through innovation and quality execution of clinical research.